Eli Lilly and Company

Event Eli Lilly and Company (LLY) Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet Feb 26, 2026 News Eli Lilly and Company (LLY) Surges 5.1% — Developing Story Feb 23, 2026 Event Eli Lilly and Company (LLY) Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz) Feb 19, 2026 Event Eli Lilly and Company (LLY) Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight Feb 18, 2026 News Eli Lilly and Company (LLY) to acquire Orna Therapeutics Feb 9, 2026 News Key highlights from Eli Lilly’s (LLY) Q4 2025 earnings results Feb 4, 2026 Transcript Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript Jan 22, 2026